BioSpace News Archive

CHARM Therapeutics today announced the promotion of Sarah Skerratt, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Laura Hare as Chief People Officer and Head of Business Operations.

Portal Biotechnologies, Inc., a cell engineering platform company, announced its emergence from stealth.

MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announces that it successfully completed its Service Organization Control 2 Type II audit.

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the completion of an oversubscribed $165 million Series C financing.

BioNTech SE will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18th, 2023.

Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc.

Neumora Therapeutics, Inc. today announced the appointment of Jason Duncan as chief legal officer.

As previously announced, BioXcel Therapeutics, Inc. will host a virtual Neuroscience R&D Day focused on BXCL502 and other neuroscience pipeline candidates. The event is set for 1:00 to 2:30 p.m. ET today, Tuesday, Dec. 12.

C4 Therapeutics, Inc. today announced that it has entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs).

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today positive results from 50 patients in two multi-center Phase 2 trials for UM171 cell therapy conducted at transplant centers in the U.S., Canada and Europe, building on prior strong data from a Phase 1/2 trial and comparative registry studies (CIBMTR and EBMT).